In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transitions In The Trial Landscape: What Will Drive RCTs Into The Clinic?

Executive Summary

Clinical trial execution is both a curse and a promise in the heated stakes for first-mover advantage in new drug development.  It’s a curse because siloed practices and legacy behaviors die hard – and it’s a promise because the volume of diverse data and a growing push for integration are finally closing the gap between research, evidence and the patient experience with disease.   New research from the Tufts University Center for the Study of Drug Development examines the struggle between these two forces and concludes that real change in the conduct of clinical trials is beginning to take root. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts